COVID-19相关药物使用-安全性监测的全球安全数据库总结:申办方视角
在报告COVID-19的病例中,免疫抑制剂/免疫调节剂、抗凝/抗血栓药和皮质类固醇最常被报告;在超说明书用于COVID-19治疗的病例中,最常报告的药物为阿奇霉素和氯喹/羟氯喹,其次为洛匹那韦-利托那韦、头孢曲松和托法替布。阿奇霉素相关病例中19%(120/645)报告了与QT延长/尖端扭转型室速相关的事件(包括7例致命性心脏事件)。
要点
- COVID-19病例中最常报告免疫抑制剂/免疫调节剂、抗凝/抗血栓药和皮质类固醇。
- 超说明书治疗COVID-19最常报告阿奇霉素和氯喹/羟氯喹。
- 阿奇霉素病例中19%(120/645)报告QT延长/尖端扭转型室速相关事件,含7例致命性心脏事件。
核心结论
- 药物警戒监测研究独特描述了与COVID-19相关的广泛药物报告病例特征。
主要发现
- 8个月期间识别超过1500例相关病例。
- 报告COVID-19的病例中,最常报告免疫抑制剂/免疫调节剂,其次为抗凝/抗血栓药和皮质类固醇。
- 超说明书用于COVID-19治疗的病例中,最常报告抗生素、抗疟药、抗病毒/抗逆转录病毒药、免疫抑制剂/免疫调节剂、皮质类固醇、抗凝药和免疫球蛋白/干扰素。
- 最常报告的药物为阿奇霉素和氯喹/羟氯喹,其次为洛匹那韦-利托那韦、头孢曲松和托法替布。
- 阿奇霉素(单用或联合氯喹/羟氯喹)最常报告的不良事件包括心电图QT延长、药物相互作用、肝炎、腹泻和急性肝炎;19%(120/645)阿奇霉素病例报告与QT延长/尖端扭转型室速相关的事件,包括7例致命性心脏事件。
临床怎么用
- 临床用药应关注免疫抑制患者COVID-19感染风险及QT延长等心脏不良事件监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Evidence-based clinical data on coronavirus disease 2019 (COVID-19) pharmacotherapies are scarce. OBJECTIVE: This study documented and characterized COVID-19 cases reported in individuals receiving treatment with Pfizer pharmaceutical products and cases that reported use of Pfizer pharmaceutical products for COVID-19 treatment. METHODS: This retrospective observational review leveraged the Pfizer safety database containing adverse event data collected in association with use of Pfizer products between 1 October, 2019, and 25 June, 2020; the database includes worldwide adverse event data from various sources. Selected Medical Dictionary for Drug Regulatory Activities (MedDRA®) Preferred Terms and subsequent clinical review were used to characterize COVID-19 cases. RESULTS: Over 1500 relevant cases were identified over an 8-month period. In cases that reported COVID-19, immunosuppressant/immunomodulating agents, followed by anticoagulant/antithrombic agents and corticosteroids, were the most frequently reported agents. The frequent reporting of immunosuppressant/immunomodulating agents among cases of COVID-19 suggests increased vulnerability to infection among treated patients, either because of immunosuppressive effects of certain agents or the nature of the underlying treated condition. In cases involving off-label pharmacotherapy use for the treatment of COVID-19-related conditions, the most frequently reported therapeutic classes included antibiotics, antimalarial agents, antivirals/antiretroviral agents, immunosuppressant/immunomodulating agents, corticosteroids, anticoagulants, and immunoglobulin/interferons. The most frequently reported pharmacotherapeutic agents were azithromycin and chloroquine/hydroxychloroquine, followed by lopinavir-ritonavir, ceftriaxone, and tofacitinib. The most frequently reported clinical adverse events associated with azithromycin (as sole therapy or combined with chloroquine/hydroxychloroquine) include electrocardiogram QT prolonged, drug interaction, hepatitis, diarrhea, and hepatitis acute. Regarding cardiac-related events, 19% (120/645) of azithromycin cases reported events associated with QT prolongation/torsade de pointes (which included seven fatal cardiac events). The most frequently reported clinical adverse events associated with other commonly used agents are also presented. CONCLUSIONS: This pharmacovigilance surveillance study provides a unique characterization of cases in which a broad range of pharmaceutical products was reported in relation to COVID-19.
引用
- Beyzarov E, Chen Y, Julg R, et al. Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective. Drug Saf. 2020. PMID: 33354753. doi:10.1007/s40264-020-01035-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。